Recap: Ultragenyx Pharmaceutical Q4 Earnings

Ultragenyx Pharmaceutical RARE reported its Q4 earnings results on Thursday, February 15, 2024 at 04:01 PM.

Here's what investors need to know about the announcement.

Ultragenyx Pharmaceutical beat estimated earnings by 6.17%, reporting an EPS of $-1.52 versus an estimate of $-1.62.

Revenue was up $24.04 million from the same period last year.

Last quarter the company missed on EPS by $0.17 which was followed by a 6.09% increase in the share price the next day.

Here's a look at Ultragenyx Pharmaceutical's past performance:

Quarter	Q3 2023	Q2 2023	Q1 2023	Q4 2022
EPS Estimate	-2.06	-2.11	-1.98	-2.14
EPS Actual	-2.23	-2.25	-2.33	-2.16
Revenue Estimate	110.02M	105.20M	104.69M	105.12M
Revenue Actual	98.05M	108.31M	100.50M	103.35M

To track all earnings releases for Ultragenyx Pharmaceutical visit their earnings calendar here.

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Calendar